Molecular Therapy

Molecular Therapy is a monthly peer-reviewed journal published by Cell Press on behalf of the American Society of Gene and Cell Therapy and established in 2000, with a 2025 Journal Impact Factor of 11.4该刊（《Molecular Therapy》）是由（Cell Press）代表（American Society of Gene and Cell Therapy）出版的同行评审月刊，2000 年创刊，2025 年影响因子为 11.4。

Scope

• It publishes original research on gene transfer, vector development and design, and stem cell manipulation该刊发表关于基因转移、载体开发与设计以及干细胞操纵的原创研究。
• It covers gene-, peptide-, protein-, oligonucleotide- and cell-based therapeutics aimed at correcting genetic and acquired diseases该刊涵盖旨在矫正遗传性与获得性疾病的基因、肽、蛋白质、寡核苷酸及细胞疗法。
• It covers vaccine development, pre-clinical target validation, and safety and efficacy studies该刊涵盖疫苗开发、临床前靶点验证以及安全性与有效性研究。
• It reports clinical trials and translational work across genetics, medicine and biotechnology该刊报道遗传学、医学与生物技术领域的临床试验与转化研究。^[1]
• Submissions are assigned to one of twelve topical subsections, among them genome editing, epigenome editing, RNA therapies and immunotherapy投稿被分配到十二个专题分栏目之一，其中包括基因组编辑、表观基因组编辑、RNA 疗法与免疫治疗。
• The journal publishes original articles, reviews, brief reports, case reports and clinical perspectives该刊发表原创研究论文、综述、简报、病例报告与临床视角文章。^[2]

History

• It was launched in 2000 by the American Society of Gene and Cell Therapy, a society founded in 1996该刊由（American Society of Gene and Cell Therapy）于 2000 年创办，该学会成立于 1996 年。
• Its founding Editor-in-Chief was Inder M. Verma of the Salk Institute for Biological Studies, who led it for its first five years其创刊主编为（Salk Institute for Biological Studies）的 Inder M. Verma，他领导该刊前五年。
• Cell Press, an imprint of Elsevier, began producing and distributing the journal in January 2017（Cell Press）作为（Elsevier）旗下品牌，自 2017 年 1 月起负责该刊的出版与发行。
• At the time of that transfer the Editor-in-Chief was Seppo Yla-Herttuala of the University of Eastern Finland该次移交时的主编为（University of Eastern Finland）的 Seppo Yla-Herttuala。
• The family now includes the sibling open-access titles Molecular Therapy Nucleic Acids, Molecular Therapy Oncology and Molecular Therapy Advances该刊族现包括姊妹开放获取刊（Molecular Therapy Nucleic Acids）、（Molecular Therapy Oncology）与（Molecular Therapy Advances）。
• It is indexed in the Science Citation Index Expanded, Scopus, PubMed and PubMed Central, and its 2025 CiteScore is 17.9该刊被（Science Citation Index Expanded）、（Scopus）、（PubMed）与（PubMed Central）收录，2025 年 CiteScore 为 17.9。

Editors

• Its Editor-in-Chief is Joseph C. Glorioso III of the University of Pittsburgh School of Medicine其主编为（University of Pittsburgh School of Medicine）的 Joseph C. Glorioso III。
• John Bell of the University of Ottawa serves as the front matter editor（University of Ottawa）的 John Bell 担任前页编辑。
• Each of the twelve subsections is led by appointed section editors drawn from universities and hospitals worldwide十二个分栏目各由来自全球大学与医院的受任栏目编辑负责。
• Beverly L. Davidson and Rebecca Ahrens-Nicklas jointly handle the clinical gene and cell therapies subsectionBeverly L. Davidson 与 Rebecca Ahrens-Nicklas 共同负责临床基因与细胞治疗分栏目。
• The board also comprises dozens of associate editors, among them researchers based in China, Germany, Finland and Australia编委会还包括数十名副编辑，其中有任职于中国、德国、芬兰与澳大利亚的研究者。
• Peer review is single-anonymized and manuscripts are submitted through Editorial Manager该刊实行单匿名同行评审，稿件通过（Editorial Manager）提交。